Blog

The Eagle Bioscience’s Coronavirus COVID-19 IgM ELISA Assay Kit was recently highlighted in a publication about a review on current diagnostic techniques for COVID-19. This review includes techniques such as RT-PCR, ddPCR, LAMP, CRISPR, and immunoassay techniques. To learn more about this publication, read below:

Abstract

Introduction
SARS-Cov-2 first appeared in Wuhan, China, in December 2019 and spread all over the world soon after that. Given the infectious nature of SARS-CoV-2, fast and accurate diagnosis tools are important to detect the virus. In this review, we discuss the different diagnostic tests that are currently being implemented in laboratories and provide a description of various COVID-19 kits.

Areas Covered
We summarize molecular techniques that target the viral load, serological methods used for SARS-CoV-2 specific antibodies detection as well as newly developed faster assays for the detection of SARS-CoV-2 in various biological samples.

Expert Opinion
In the light of the widespread pandemic, the massive diagnosis of COVID-19, using various detection techniques, appears to be the most effective strategy for monitoring and containing its propagation.

Jaddaoui, IE., Allali, M., Raoui, S., et al. A review on current diagnostic techniques for COVID-19. Expert Review of Molecular Diagnostics. (2021) 21:2, 141-160.

If you have any questions about this Coronavirus COVID-19 IgM ELISA Assay Kit or our other products, contact use here!

The Eagle Bioscience’s TNF-Alpha ELISA Assay Kit was recently utilized in a publication about the detection rate and genotyping of Cryptosporidium spp. and its relation to corporate TNF-Alpha in elderly Egyptians.

Abstract

Background
Elderly individuals are considered an at-risk population, susceptible to enteric infections; and Cryptosporidium spp. is an apicomplexan protozoan considered to be one of the most common protozoa causing diarrhea. Cryptosporidiosis causes elevation of many pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) which may play a role in pathogenesis of the disease.

Objectives
This study was designed for detection and genotyping of Cryptosporidium spp. in elderly patients and the relationship of infection with copro TNF-α. Diagnosis was by evaluation of permanent acid-fast cold Kinyoun’s (AF) staining, immunochromatographic detection (ICT), and ELISA in comparison to molecular diagnosis as gold standard diagnostic method.

Subjects and Methods
Stool samples were collected from 270 elderly patients aged above 60 years old attending outpatient clinics of Internal Medicine Hospital, Cairo University. Sample were examined microscopically by direct wet mount, and AF straining, and then subjected to ICT ELISA and nested PCR (nPCR) assays. Positive samples by nPCR were then subjected to Restriction fragment length polymorphism (RELP) to detect Cryptosporidium genotypes. Corpo-levels of TNF-Alpha were measured to asses their relationship with cryptosporidiosis.

Results
Cryptosporidiosis detection rates of 3.7%, 6.3%, 6.7%, 3.7% were determined by microscopic examination after AF staining, ICT, ELISA and nPCR, respectively. When RFLP was performed on nPCR positive samples, eight and two samples were assigned as genotype 1 and 2, respectively. Moreover, TNF-α was significantly correlated with cryptosporidiosis.

Conclusion
Conclusion: The elderly are highly vulnerable to cryptosporidiosis. Immunodiagnosis and molecular techniques are fundamental for the diagnosis of cryptosporidiosis. Cryptosporidiosis significantly affects copro TNF-α.

Amin, NM., Raafat, A., Morsy, SM. Detection rate and genotyping of Cryptosporidium spp. and its relation to copro TNF-α in elderly Egyptians attending outpatient clinics of Cairo University Hospitals. Parasitologists. (2021)14:77-85

If you have any questions about this product or our other offerings, contact us here.

The Eagle Bioscience’s Anti-Infliximab ELISA Assay Kit was recently highlighted in a publication about factors that are associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders.

Abstract

Background
Inadequate systemic exposure to infliximab (IFX) is associated with treatment failure. This work evaluated factors associated with reduced IFX exposure in children with autoimmune disorders requiring IFX therapy.

Methods
In this single-center cross-sectional prospective study IFX trough concentrations and anti-drug antibodies (ADAs) were measured in serum from children diagnosed with inflammatory bowel disease (IBD) (n = 73), juvenile idiopathic arthritis (JIA) (n = 16), or uveitis (n = 8) receiving maintenance IFX infusions at an outpatient infusion clinic in a tertiary academic pediatric hospital. IFX concentrations in combination with population pharmacokinetic modeling were used to estimate IFX clearance. Patient demographic and clinical data were collected by chart review and evaluated for their relationship with IFX clearance.

Results
IFX trough concentrations ranged from 0 to > 40 μg/mL and were 3-fold lower in children with IBD compared to children with JIA (p = 0.0002) or uveitis (p = 0.001). Children with IBD were found to receive lower IFX doses with longer dosing intervals, resulting in dose intensities (mg/kg/day) that were 2-fold lower compared to children with JIA (p = 0.0002) or uveitis (p = 0.02). Use of population pharmacokinetic analysis to normalize for variation in dosing practices demonstrated that increased IFX clearance was associated with ADA positivity (p = 0.004), male gender (p = 0.02), elevated erythrocyte sedimentation rate (ESR) (p = 0.02), elevated c-reactive protein (CRP) (p = 0.001), reduced serum albumin concentrations (p = 0.0005), and increased disease activity in JIA (p = 0.009) and IBD (p ≤ 0.08). No significant relationship between diagnosis and underlying differences in IFX clearance was observed. Multivariable analysis by covariate population pharmacokinetic modeling confirmed increased IFX clearance to be associated with anti-IFX antibody positivity, increased ESR, and reduced serum albumin concentrations.

Conclusions
Enhanced IFX clearance is associated with immunogenicity and inflammatory burden across autoimmune disorders. Higher systemic IFX exposures observed in children with rheumatologic disorders are driven primarily by provider drug dose and interval selection, rather than differences in IFX pharmacokinetics across diagnoses. Despite maintenance IFX dosing at or above the standard recommended range for IBD (i.e., 5 mg/kg every 8 weeks), the dosing intensity used in the treatment of IBD is notably lower than dosing intensities used to treat JIA and uveitis, and may place some children with IBD at risk for suboptimal maintenance IFX exposures necessary for treatment response.

Funk, RS., Shakhnovich, V., Cho, YK., et al. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmun disorders: a cross-sectional prospective convenience sampling study. Pediatric Rheumatology. (2021) 19:62

If you have any questions about the Anti-Infliximab ELISA Assay Kit or our other offerings, contact us here.

The Eagle Bioscience’s Calprotectin ELISA Assay Kit was highlighted in a recent study! In this publication scientists studied the dose effect of bovine lactoferrin (bLF) fortification on diarrhea and respiratory tract infections in weaned infants with anemia.

Abstract

Objective
The aim of this study was to explore the dose effect of bovine lactoferrin (bLF) fortification on the morbidity of diarrhea and respiratory tract infections in weaned infants with anemia.

Methods
A total of 108 infants with anemia, who were exclusively breast fed at 4 to 6 months and weaned and formula fed at 6 to 9 months, were recruited. The eligible infants were randomly assigned to fortified group 0 (FG0), fortified group 1 (FG1), or fortified group 2 (FG2) and were given formula fortified with 0 mg/100 g, 38 mg/100 g, and 76 mg/100 g of bLF, respectively, for 3 mo. The morbidity of diarrhea and respiratory tract infections (RTIs), the duration of respiratory and diarrhea-related illnesses, and the levels of fecal human beta-defensin 2 (HBD-2), cathelicidin LL-37 (LL-37), secretory IgA (sIgA), butyrate, and calprotectin were assessed.

Results
After the exclusion of 12 dropouts, the primary outcome measures, including episodes and duration of diarrhea and RTIs during the intervention, were obtained from 96 infants (35, 33, and 28 in FG0, FG1, and FG2, respectively). Compared with infants in FG0, there was a lower morbidity of rhinorrhea, wheezing, and skin rash among infants in FG1 (P < 0.05) and a lower morbidity of respiratory-related illness and wheezing among infants in FG2 (P < 0.05). Furthermore, a lower morbidity of diarrhea-related illness, diarrhea, vomiting, and nausea was observed among infants in FG2 than those in the other two groups (P < 0.05). In addition, the FG1 infants had a lower morbidity of vomiting and nausea than the FG0 infants (P < 0.05). The HBD-2, LL-37, sIgA, and calprotectin levels were significantly higher whereas the butyrate level was significantly lower in the FG2 infants than in infants in the other two groups after 3 mo of intervention (P < 0.05).

Conclusions
The bLF-fortified formula was effective in reducing the morbidity of diarrhea and RTIs in infants with anemia, with the 76 mg/100 g bLF-fortified formula exhibiting a stronger effect. The bLF fortification could be a new strategy for the prevention of diarrhea and RTIs in infants with anemia.

Chen, K., Jin, S., Chen, H.,et al. Dose effect of bovine lactoferrin fortification on diarrhea and respiratory tract infections in weaned infants with anemia: A randomized, controlled trial. Nutrition. (2021)90:111288

If you have any questions about this product or our other offerings, contact us here.